4D Molecular Therapeutics(FDMT)
Focus: 4D Molecular Therapeutics is a publicly traded gene therapy company focused on treating rare and serious diseases including retinal dystrophies, Fabry disease, and cystic fibrosis. The company operates at preclinical to Phase 3 stage with a lean, R&D-focused operation.
Profile data last refreshed 58m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
10+4 this month
Stable — net +4 jobs in 30d
13 added, 9 removed. Backfill posture.
Should You Work at 4D Molecular Therapeutics?
AI assessmentBest suited for scientists/clinicians betting on gene therapy success; risky for career stability seekers given cash runway and lack of near-term revenue inflection.
Why Work Here
- Pioneering gene therapy platform with 6 active programs across high-need indications, offering exposure to cutting-edge molecular therapeutics development
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$37K
Pipeline & Clinical Trials
Observation
ChoroideremiaClinical Trials (2)
NCT045171494D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
Phase 1/2Help build intelligence for 4D Molecular Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.